BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20223551)

  • 1. The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
    Lee JJ; Maeng CH; Baek SK; Kim GY; Yoo JH; Choi CW; Kim YH; Kwak YT; Kim DH; Lee YK; Kim JB; Kim SY
    Lung Cancer; 2010 Nov; 70(2):205-10. PubMed ID: 20223551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients].
    Gao Z; Han B; Shen J; Gu A; Zhong H
    Zhongguo Fei Ai Za Zhi; 2011 Apr; 14(4):340-4. PubMed ID: 21496433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.
    Dong S; Guo AL; Chen ZH; Wang Z; Zhang XC; Huang Y; Xie Z; Yan HH; Cheng H; Wu YL
    J Hematol Oncol; 2010 Mar; 3():10. PubMed ID: 20226083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.
    Nie X; Cheng G; Ai B; Zhang S
    Cancer Biomark; 2013 Jan; 13(6):433-40. PubMed ID: 24595080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
    Shi Y; Chen L; Li J; Lü YL; Jiao SC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer.
    Xu XL; Zhang YP; Fang Y; Su D; Chen W; Feng JG; Li ZP; Mao WM
    J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C49-55. PubMed ID: 26323924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of ribonucleotide reductase subunit M1 (RRM1) in non-small cell lung cancer: A meta-analysis.
    Zhu CM; Lian XY; Bi YH; Hu CC; Liang YW; Li QS
    Clin Chim Acta; 2018 Oct; 485():67-73. PubMed ID: 29803896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.
    Dong X; Hao Y; Wei Y; Yin Q; Du J; Zhao X
    PLoS One; 2014; 9(3):e92320. PubMed ID: 24647522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum.
    Wang LR; Zhang GB; Chen J; Li J; Li MW; Xu N; Wang Y; Shen Tu JZ
    J Zhejiang Univ Sci B; 2011 Mar; 12(3):174-9. PubMed ID: 21370501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma.
    Zhao LP; Xue C; Zhang JW; Hu ZH; Zhao YY; Zhang J; Huang Y; Zhao HY; Zhang L
    Chin J Cancer; 2012 Oct; 31(10):476-83. PubMed ID: 22692073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients--a short report.
    Zeng C; Fan W; Zhang X
    Cell Oncol (Dordr); 2015 Aug; 38(4):319-25. PubMed ID: 26092210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis.
    Gong W; Zhang X; Wu J; Chen L; Li L; Sun J; Lv Y; Wei X; Du Y; Jin H; Dong J
    Lung Cancer; 2012 Mar; 75(3):374-80. PubMed ID: 21889227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer.
    Wang X; Zhao J; Yang L; Mao L; An T; Bai H; Wang S; Liu X; Feng G; Wang J
    Med Oncol; 2010 Jun; 27(2):484-90. PubMed ID: 19488864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
    Pesta M; Kulda V; Fiala O; Safranek J; Topolcan O; Krakorova G; Cerny R; Pesek M
    Anticancer Res; 2012 Nov; 32(11):5003-10. PubMed ID: 23155271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum.
    Ryu JS; Shin ES; Nam HS; Yi HG; Cho JH; Kim CS; Kim HJ; Lee JE
    J Thorac Oncol; 2011 Aug; 6(8):1320-9. PubMed ID: 21642870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer.
    Feng JF; Wu JZ; Hu SN; Gao CM; Shi MQ; Lu ZH; Sun XC; Zhou JR; Chen BA
    Lung Cancer; 2009 Dec; 66(3):344-9. PubMed ID: 19304340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
    Tokunaga Y; Liu D; Nakano J; Zhang X; Nii K; Go T; Huang CL; Yokomise H
    Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC.
    Vilmar A; Garcia-Foncillas J; Huarriz M; Santoni-Rugiu E; Sorensen JB
    Lung Cancer; 2012 Mar; 75(3):306-12. PubMed ID: 21996087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relationship between the efficacy of gemcitabine/cisplatin adjuvant chemotherapy and RRM1 protein expression in postoperative NSCLC patients].
    Ma K; Li E; Guo Y; Wang X; Sun H; Shao G
    Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):505-10. PubMed ID: 25327655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.
    Kim SO; Jeong JY; Kim MR; Cho HJ; Ju JY; Kwon YS; Oh IJ; Kim KS; Kim YI; Lim SC; Kim YC
    Clin Cancer Res; 2008 May; 14(10):3083-8. PubMed ID: 18483375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.